Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00441662 · ClinicalTrials.gov registry record · NA
Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema
A NA study, sponsored by Wills Eye.
- Completed
- Registry status
- NA
- Development phase
- 170
- Enrollment target
NCT00441662: Completed NA study, sponsored by Wills Eye.
NCT00441662 is a NA study that has completed, run by Wills Eye. The registered enrollment target is 170 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00441662, a NA study, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- NA
- Development phase
- 170 participants
- Enrollment target
Study Summary
Melanoma is the most common primary tumour which occurs inside the eye. For over 20-years, it has been possible, in many cases, to use local delivery of radiation to the eye to treat this type of tumour, avoiding the need to surgically remove the affected eye. This treatment, however, is often complicated by radiation-induced loss of vision, months or years after treatment. The aim of this research project is to investigate the potential prevention of radiation complications in the eye by giving anti-inflammatory medication (a long-acting steroid) in the form of a local injection around the eye at the time of treatment, and at 4-months and 8-months following treatment. This medication (named 'triamcinolone') has been successfully used to treat similar complications of diabetic eye disease, for example, and has a good safety profile. The rationale of this study is to attempt to preserve vision, in addition to preserving the eye, in patients affected by this eye tumour, and therefore preserve quality of life for these patients.
Interventions
- DRUG Sub-Tenon triamcinolone 40mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2004-11 |
| Est. Completion | 2007-05 |
| Phase | NA |
What the finished NCT00441662 record still lists
NCT00441662 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which Sub-Tenon triamcinolone 40mg is the first listed.
NCT00441662 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00441662 about?
NCT00441662 is a clinical study titled "Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema". Melanoma is the most common primary tumour which occurs inside the eye. For over 20-years, it has been possible, in many cases, to use local delivery of radiation to the eye to treat this type of tumour, avoiding the need to surgically remove the affected eye. This treatment, however, is often compl...
What is the current status of trial NCT00441662?
This trial is currently completed. It is a NA study. The enrollment target is 170 participants. The study started on 2004-11. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00441662?
The interventions under investigation include: Sub-Tenon triamcinolone 40mg (DRUG).
Who is sponsoring clinical trial NCT00441662?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00441662's enrollment target sits among peer trials
170 614th of 2000 higher than 1,382 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia